PBYI

Puma Biotechnology, Inc. (PBYI) - Q2 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Quarterly Report on Form 10-Q for Puma Biotechnology, Inc. for the period ended June 30, 2026. Puma is a biopharmaceutical company focused on the commercialization of NERLYNX® (neratinib) for HER2-positive breast cancer and the global development of alisertib, an Aurora Kinase A inhibitor licensed from Takeda. The company operates as a single reporting segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 7.8% in Q2 2026 compared to Q2 2025, driven by a 9.0% increase in net product revenue ($53.6M vs $49.2M). This was due to a 12.3% increase in domestic bottles sold and higher selling prices, partially offset by increased variable consideration deductions (primarily Medicaid rebates).
• R&D Expense Increase: Research and development expenses rose 22.3% in Q2 2026 ($18.9M) compared to Q2 2025 ($15.5M). The increase was primarily due to higher clinical trial expenses ($2.2M increase) related to alisertib study activity and increased internal R&D costs.
• Debt Elimination: On May 4, 2026, the company paid off the remaining principal, interest, and exit fees ($11.5M total) on its Athyrium Note Purchase Agreement, reducing long-term debt to zero ahead of the July 2026 maturity date.
• SG&A Reduction: Selling, general, and administrative expenses decreased 2.8% in Q2 2026 ($17.5M vs $18.0M), largely due to reduced facility costs following the termination of the San Francisco office lease and a reduction in Los Angeles space.

Outlook, Risks, and Contingencies

• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($93.9M) combined with expected product sales and sub-license payments are sufficient to fund operations for at least one year.
• Patent Litigation (AstraZeneca): On July 9, 2026, the Federal Circuit affirmed the Delaware District Court's judgment holding the '314 and '162 patents (related to Tagrisso®) invalid. While the company disagrees with the ruling, it may seek further review. The company maintains contractual rights to recover damages under its license with Pfizer.
• China Generic Competition: Multiple generic versions of NERLYNX have been approved in China (Acebright, Aosaikang, Convalife, Kelun, Demai). The company notes that royalty rates from its China sub-licensee are subject to reduction once generic market share reaches a specified threshold, which could occur in late 2026 or 2027.
• Tariff Risks: A U.S. government proclamation imposes a 100% ad valorem duty on imported patented pharmaceutical products, effective July 31, 2026, for certain large companies. The company is reviewing the potential impact, though it currently does not believe tariffs will have a material impact.
• Alisertib Development: The company continues to advance alisertib, having initiated Phase II trials for small cell lung cancer (ALISCA-Lung1) and hormone receptor-positive breast cancer (ALISCA-Breast1).

Key Investor Verification Points

• Debt Status: Confirm the complete extinguishment of the Athyrium debt and the absence of new debt obligations.
• China Royalty Exposure: Monitor the timeline for the royalty rate reduction trigger in China as generic market share increases.
• Patent Validity: Assess the potential financial impact of the Federal Circuit's invalidation of the AstraZeneca patents and the likelihood of further appeals.
• Alisertib Milestones: Track progress in the ALISCA-Lung1 and ALISCA-Breast1 Phase II trials, as these drive future R&D spend and potential milestone payments to Takeda.
• Tariff Implementation: Verify the final impact of the Section 232 tariffs on the cost of goods sold for NERLYNX.